We’ll be recapping some of the top news presented each day during the conference—and soon we’ll speak with Dr Leora Horn on the pivotal lung cancer updates being presented, and Dr Elizabeth Plimack on intriguing data in genitourinary cancers.

Welcome to OncLive News Network! I’m Gina Columbus.

Findings presented at the meeting showed that a broader set of clinical trial eligibility criteria proposed by ASCO and Friends of Cancer Research would nearly double the number of patients with advanced non—small cell lung cancer who were available for enrollment.

In ASCO’s CancerLinq database, investigators found that, under the expedited criteria, 98.5% of patients would be accepted for advanced NSCLC trials versus 52.3% under traditional criteria.

In colorectal cancer, the long-term survival rates for those with liver metastases were similar regardless of whether patients underwent laparoscopic or open liver surgery.

Results had showed that the median overall survival in the laparoscopic surgery arm was 80 months compared with 81 months in those who underwent open heart surgery.

The antibody-drug conjugate enfortumab vedotin led to a 44% overall response rate and a median overall survival of 11.7 months in patients with locally advanced or metastatic urothelial carcinoma in a single-arm, 2-cohort trial.

The FDA granted a breakthrough therapy designation to enfortumab vedotin for this patient population that has progressed during or following checkpoint inhibition, based on phase I data.

The Society of Gynecologic Oncology released a study showing that more than 70% of female gynecologic oncologists in the United States and more than half of male practitioners have experienced sexual harassment either in clinic or practice.

Women were found to be more likely to report harassment, which was not statistically significant, and 40% of responders did not report incidents to officials, because it did not seem important enough to them.

In EGFR-mutant non—small cell lung cancer, results of the RELAY trial showed that the frontline combination of ramucirumab plus erlotinib improved progression-free survival compared with ramucirumab and placebo in EGFR-mutant metastatic NSCLC.

Moreover, the safety findings were consistent with the established tolerability profiles of each agent alone.

Single-agent olaparib had a significant and clinically relevant improvement in overall survival in patients with germline BRCA-mutant platinum-sensitive relapsed ovarian cancer. All patients who received the PARP inhibitor alone had a significant, clinically relevant improvement in overall response rate and progression-free survival compared with chemotherapy of physician’s choice. No new safety signals were identified.

For a full review of all of these studies, please visit OncLive.com.

And don’t forget!

The OncLive Global Expo is taking place October 11th through 13th in Orlando, Florida. Join us for a fully interactive meeting that brings together the most inclusive group of oncology professionals to collaborate on emerging trends and technologies in oncology care and research.

Thank you for watching OncLive News Network! I’m Gina Columbus.